High prevalence of colonization with livestock-associated (LA) methicillin-resistant *Staphylococcus aureus* (MRSA) sequence type (ST) 398 among pigs and pig farmers was first reported in the Netherlands ([@R1]) and has since been identified in Canada ([@R2]) and the United States ([@R3]). In Canada, this LA-MRSA strain was identified in pigs and pig farmers in southwestern Ontario, where prevalence of MRSA colonization was 24.9% (71/285) and 20% (5/25), respectively ([@R2]). In the United States, nasal samples from 20 production system workers and 299 swine from 2 farms in Illinois and Iowa showed that 45% (9/20) and 49% (147/299), respectively, were colonized with LA-MRSA ([@R3]). Despite such high prevalence of MRSA colonization on these tested farms, to our knowledge, no human or animal infections resulting from LA-MRSA strains have been reported in North America.

To determine whether LA-MRSA has recently emerged in the general population of Canada, we identified human infections and colonizations associated with the LA-MRSA strain in Canada and molecularly characterized the isolates. We also identified a novel staphylococcal cassette chromosome (SCC) *mec*V subtype harboring clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated genes (*cas*).

Materials and Methods
=====================

A convenience sample, totaling 2,358 MRSA isolates from human specimens, was submitted to the National Microbiology Laboratory (NML) for *spa* typing, as described ([@R4],[@R5]). During January 2007--October 2008, the Saskatchewan Disease Control Laboratory submitted 2,008 specimens; during October 2007--August 2008, the Cadham Provincial Laboratory in Manitoba submitted 350 specimens. An additional 1,329 isolates from human specimens were *spa* typed by the Saskatchewan Disease Control Laboratory.

Given the client base of the Cadham Provincial Laboratory, most of these isolates would have originated from colonized and infected persons living in the community or in personal-care homes or from persons hospitalized in smaller community hospitals, whereas, for surveillance purposes, the Saskatchewan Disease Control Laboratory receives isolates from all colonized and infected persons across the province. Detailed information regarding why cultures were taken (e.g., screening admissions, outbreak investigations) and other clinical and epidemiologic data were limited. Isolates typed in this study represented ≈17% of all MRSA isolates from persons in Manitoba and ≈66% of all MRSA isolates from persons in Saskatchewan within the study period. An additional isolate was sent to the NML from Sunnybrook Health Sciences Centre in Ontario for reference purposes.

Isolates with *spa* types associated with ST398 were confirmed by multilocus sequence typing; tested for Panton-Valentine leukocidin toxin, *mec*A, and *nuc* genes; and typed for SCC*mec* as described ([@R6]--[@R9]). Pulsed-field gel electrophoresis (PFGE) of *Sma*I- or *Cfr*91-digested genomic DNA was conducted as described ([@R10]). Antimicrobial drug susceptibility testing was conducted by using standard broth microdilution panels according to Clinical and Laboratory Standards Institute guidelines ([@R11]). Breakpoints for fusidic acid and mupirocin resistance, which were not provided in the guidelines, were as described ([@R12],[@R13]).

A fosmid library was constructed by cloning sheared genomic DNA from *S. aureus* isolate 08 BA 02176 into the pCC2FOS vector. The fosmid clones were screened by PCR to identify specific genes *orfX*, *mecA*, and the chromosomal region located downstream of SCC*mec*. Fosmid clone 1G1 was identified and contained the entire SCC*mec* region of the 08 BA 02176 isolate. Colonies were prepared by using the CopyControl Fosmid Library Production Kit (Epicenter Biotechnologies, Madison, WI, USA) according to the manufacturer's instructions. Fosmid DNA was column purified by using a QIAGEN Plasmid Mini Kit (QIAGEN, Valencia, CA, USA).

DNA sequencing was performed on the ABI3730xl genetic analyzer (Applied Biosystems, Foster City, CA, USA). Staden (Pregap4) software was used to prepare trace data for sequence assembly ([@R14]). Sequencing reads were assembled by using the Staden Gap4 program. Gap closure was achieved by primer walking and long-range PCR. Specific primers were designed near the ends of neighboring contigs (contiguous sequence of DNA created by overlapping sequenced fragments of a chromosome), and PCRs were performed with chromosomal template DNA. Regions containing putative frameshifts and point mutations were resequenced to verify the fidelity of the sequence.

Annotation and data mining of the *S. aureus* 08 BA 02176 1G1 fosmid clone sequence were performed by using the GenDB version 2.2 annotation tool ([@R15]). Putative protein coding sequences were determined according to coding sequence predictions of Glimmer, which is integrated into the GenDB package. Similarity searches were performed by using BLASTN and BLAST2P ([www.ncbi.nlm.nih.gov/blast/Blast.cgi](http://www.ncbi.nlm.nih.gov/blast/Blast.cgi)) against the nonredundant nucleotide and protein databases, respectively. Additionally, a BLAST2P search was performed against the databases nr (<ftp://ftp.ncbi.nlm.nih.gov/blast/db>/), SWISS-PROT ([www.expasy.ch/sprot/](http://www.expasy.ch/sprot/)), and KEGG-Genes (<ftp://ftp.genome.jp/pub/kegg/genes/>); the protein family databases Pfam (<http://pfam.sanger.ac.uk/>) and TIGRFAM ([www.jcvi.org/cms/research/projects/tigrfams/overview/](http://www.jcvi.org/cms/research/projects/tigrfams/overview/)); and predictive signal peptide (Signal P \[[www.cbs.dtu.dk/services/SignalP/](http://www.cbs.dtu.dk/services/SignalP/)\]) and transmembrane helix analysis (TMHMM \[[www.cbs.dtu.dk/services/TMHMM/](http://www.cbs.dtu.dk/services/TMHMM/)\]), the nonredundant database on protein level. An automatic functional annotation was followed by a manual annotation of each predicted gene.

Results
=======

LA-MRSA Characterization
------------------------

A total of 3,687 MRSA isolates were examined; 5 contained ST398-associated *spa* types (4 t034 and 1 t1250). The additional isolate submitted to NML by Sunnybrook Health Sciences Centre in Ontario, isolate T40929, also contained a t034 *spa* type. Further molecular characterization of these 6 isolates determined that they were all ST398, SCC*mec*V, and negative for the Panton-Valentine leukocidin--encoding genes ([Table 1](#T1){ref-type="table"}). Of the 6 isolates, 5 were resistant to tetracycline, but all were susceptible to the other 12 antimicrobial drugs tested ([Table 2](#T2){ref-type="table"}).

###### Characteristics of methicillin-resistant *Staphylococcus aureus* sequence type 398 novel staphylococcal cassette chromosome *mec*V subtype isolates, Canada\*

  Isolate       Collection date   Patient age, y/sex   Region and province          Specimen collection site        *spa* type
  ------------- ----------------- -------------------- ---------------------------- ------------------------------- ------------
  07 BA 06477   2007 Feb 27       26/F                 Saskatoon, SK                Nasal screen                    t034
  08 BA 02176   2008 Jan 15       71/F                 Sunrise, SK                  Leg swab                        t034
  08 BA 08100   2008 Mar 4        51/M                 Five Hills, SK               Left shin open abrasion         t1250
  08 BA 13895   2008 Apr 25       79/M                 Kelsey Trail, SK             Left hip swab                   T034
  08 BA 22334   2008 Jul 9        70/M                 Prince Albert Parkland, SK   Right leg swab                  T034
  T40929        2007 Dec 11       59/M                 Durham, ON                   Nasal and tracheostomy screen   T034

\*All isolates were Panton-Valentine leukocidin negative. SK, Saskatchewan; ON, Ontario.

###### Antimicrobial drug susceptibility of the clinical isolates of methicillin-resistant *Staphylococcus aureus* sequence type 398, Canada, 2008\*

  Drug             Susceptibility, μg/mL                                                                   
  ---------------- ----------------------- --------------- --------------- --------------- --------------- ---------------
  Clindamycin      [\<]{.ul}0.25           [\<]{.ul}0.25   [\<]{.ul}0.25   [\<]{.ul}0.25   [\<]{.ul}0.25   [\<]{.ul}0.25
  Vancomycin       0.5                     0.5             0.5             0.5             0.5             0.5
  Erythromycin     0.5                     0.5             0.5             0.5             0.5             0.5
  SXT              [\<]{.ul}0.25           [\<]{.ul}0.25   [\<]{.ul}0.25   [\<]{.ul}0.25   [\<]{.ul}0.25   [\<]{.ul}0.25
  Synercid         0.5                     1               [\<]{.ul}0.25   [\<]{.ul}0.25   [\<]{.ul}0.25   [\<]{.ul}0.25
  Nitrofurantoin   [\<]{.ul}32             [\<]{.ul}32     [\<]{.ul}32     [\<]{.ul}32     [\<]{.ul}32     [\<]{.ul}32
  Tetracycline     \>16                    \>16            \>16            ≤2              \>16            \>16
  Ciprofloxacin    0.5                     0.25            0.5             0.25            0.5             0.5
  Rifampin         [\<]{.ul}0.25           [\<]{.ul}0.25   [\<]{.ul}0.25   [\<]{.ul}0.25   [\<]{.ul}0.25   [\<]{.ul}0.25
  Fusidic acid     0.25                    0.12            0.25            0.12            0.12            0.12
  Linezolid        2                       2               2               1               0.5             0.5
  Gentamicin       1                       1               1               1               ≤0.5            1
  Mupirocin        0.5                     0.25            [\<]{.ul}0.12   [\<]{.ul}0.12   0.25            [\<]{.ul}0.12

\*SXT, sulfamethoxazole/trimethoprim.

From the surveillance in Manitoba and Saskatchewan, patient information was limited and showed no geographic links (all 5 persons resided in different health regions but were all within the southeastern portion of Saskatchewan) ([Figure 1](#F1){ref-type="fig"}). Of the 5 isolates, 4 were obtained from infected persons (average age 67.8 years, range 51--79 years) ([Table 1](#T1){ref-type="table"}). The earliest identified LA-MRSA isolate (08 BA 2176) associated with an infection was obtained from a postoperative surgical site. Further follow-up was not possible because of the patient's health problems. This patient is unlikely to have had any recent direct contact with livestock because she had been confined to her home with limited mobility for several years before her hospitalization. Additional nasal swabs from this patient remained positive for this strain for at least 7 months. Additional clinical and epidemiologic information for the remaining 3 patients with skin and soft tissue or wound infections were limited ([Table 1](#T1){ref-type="table"}).

![Geographic distribution of 5 livestock-associated methicillin-resistant *Staphylococcus aureus* isolates (stars) from humans, Saskatchewan, January 2007--October 2008.](09-1435-F1){#F1}

The isolate submitted to the NML by Sunnybrook Health Sciences Centre, outside the surveillance program, was from a 59-year-old man from Ontario. He had been hospitalized in December 2007 for treatment of metastatic squamous cell carcinoma of the larynx. In the previous year, he had undergone a total laryngectomy, neck node dissection, and tracheostomy. A MRSA isolate was recovered from screening specimens from his nose and the tracheostomy site that had no indication of infection. He was unaware of any animal contact and had no history of exposure to pigs or pig farms. A review of the medical records and standard epidemiologic investigations determined that this was not a nosocomial or healthcare-associated isolate.

The 6 LA-MRSA isolates were nontypeable by PFGE using *Sma*I. However, PFGE using the neoschizomer *Cfr*91 showed that the 6 LA-MRSA isolates were closely related ([Figure 2](#F2){ref-type="fig"}, panel A). Control MRSA strains digested individually with either *Cfr*91 or *Sma*I showed no differences in fingerprint banding patterns when the 2 enzymes were compared (data not shown), which enabled comparisons of the PFGE patterns obtained for the LA-MRSA isolates with those of other epidemic MRSA strains from hospitals and communities in Canada. No close relatedness was found ([\>]{.ul}7 bands difference; \<80% similarity) between the LA-MRSA isolates and any other epidemic MRSA strain circulating in Canada ([Figure 2](#F2){ref-type="fig"}, panel B).

![A) Pulsed-field gel electrophoresis (PFGE) of *Cfr*91-digested livestock-associated methicillin-resistant *Staphylococcus aureus* (MRSA). Lanes 1, 6, and 9, universal standard *Salmonella* Braenderup H9812; Lane 2, 08 BA 02176; Lane 3, 08 BA 13895; Lane 4, 07 BA 06477; Lane 5, T40929; Lane 7, 08 BA 08100; Lane 8, 07 BA 22334. B) PFGE dendrogram comparing the *Cfr*91 fingerprint patterns of 6 livestock-associated MRSA isolates from humans in Canada with the *Sma*I fingerprints of other human epidemic strains of MRSA circulating in Canada.](09-1435-F2){#F2}

SCC*mec* Characterization
-------------------------

DNA sequencing of the entire SCC*mec* element from isolate 08 BA 02176 showed a 32,369-bp element integrated at the 3′ end of *orf*X containing 30 putative open reading frames (ORFs) ([Figure 3](#F3){ref-type="fig"}; [Table 3](#T3){ref-type="table"}). This element carried a class C2 *mec* complex, which putatively contained a nonfunctional IS431 transposase and a type 5 *ccr* gene complex (*ccr*C2). Other than *mecA*, no additional antimicrobial drug resistance genes were identified within this element.

![Schematic of the novel staphylococcal cassette chromosome (SCC) *mec*V subtype and DNA sequence of the clustered regularly interspaced short palindromic repeat (CRISPR) array identified in *Staphylococcus aureus* isolate 08 BA 02176. Red and green arrows represent *mec* and *ccr* complexes, respectively. Blue arrows represent 3 open reading frames (ORFs) in the J3 region sharing sequence identity with chromosomal genes of *S. epidermidis* RP62A. Orange boxes indicate confirmed and questionable CRISPRs. Black arrows represent CRISPR-associated genes. Location of primer sets used for coverage of this SCC*mec* element are numbered 1--11 ([Table 4](#T4){ref-type="table"}) and illustrated as solid lines. Shown below the schematic is the DNA sequence of the confirmed 1,107-bp CRISPR array in the J1 region, which provides the 36-bp direct repeat consensus (**boldface**) and the variable 15 spacer sequences.](09-1435-F3){#F3}

###### Open reading frames of the novel staphylococcal cassette chromosome *mec*V subtype in methicillin-resistant *Staphylococcus aureus* isolate 08 BA 02176, from woman in Canada, 2008\*

  ORF    Location, bp†    Predicted gene size, bp   Gene‡      Product description                                                 Amino acid identity, %§   GenBank accession no.
  ------ ---------------- ------------------------- ---------- ------------------------------------------------------------------- ------------------------- -----------------------
  Sk01   1--480           480                       *orfX*     Conserved hypothetical protein                                      100                       gb\|ACC96139.1\|
  Sk02   609--1595        987                       None       ADP-ribosylglycohydrolase                                           99                        gb\|AAW53059.1\|
  Sk03   1614--2948       1335                      None       Permease for cytosine/purines; uracil; thiamine; allantoin          98                        gb\|AAW53058.1\|
  Sk04   2999--3883       885                       None       Ribokinase                                                          98                        gb\|AAW53057.1\|
  Sk05   (4013--4687)     675                       *tnp*      Transposase for IS431                                               100                       dbj\|BAD24823.1\|
  Sk06   4945--5112       168                       None       HMG-CoA synthase truncation                                         100                       ref\|YP_184940.1\|
  Sk07   6029--6772       744                       *ugpQ*     Glycerophosphoryl diester phosphodiesterase                         100                       ref\|NP_370563.1\|
  Sk08   6869--7297       429                       *maoC*     Hypothetical protein                                                100                       ref\|YP_184943.1\|
  Sk09   (7343--9349)     2007                      *mecA*     Penicillin-binding protein 2′                                       100                       dbj\|BAG06200.1\|
  Sk10   9449--9559       Unknown                   ψ*mecR1*   Truncated signal transducer protein MecR1                           100                       ref\|YP_252007.1\|
  Sk11   9597--9740       144                       ψ*tnp*     Partial transposase for insertion sequence--like element IS431mec   100                       dbj\|BAH57698.1\|
  Sk12   (10331--10759)   429                       None       Hypothetical protein                                                100                       dbj\|BAD24829.1\|
  Sk13   10840--11769     930                       None       Hypothetical protein                                                100                       gb\|ACL99839.1\|
  Sk14   11931--13919     1989                      None       Hypothetical protein                                                100                       gb\|ACL99840.1\|
  Sk15   14114--15223     1110                      None       Hypothetical protein                                                100                       gb\|ACL99841.1\|
  Sk16   15584--17200     1617                      None       Hypothetical protein                                                100                       gb\|ACL99843.1\|
  Sk17   17425--19104     1680                      *ccrC*     Cassette chromosome recombinase C                                   100                       gb\|ACL99844.1\|
  Sk18   19193--19531     339                       None       Hypothetical protein                                                100                       gb\|ACL99845.1\|
  Sk19   19625--19936     312                       None       Hypothetical protein                                                100                       gb\|ACL99846.1\|
  Sk20   19951--20454     504                       None       Hypothetical protein                                                100                       gb\|ACL99847.1\|
  Sk21   20469--20690     222                       None       Hypothetical protein                                                100                       gb\|ACL99848.1\|
  Sk22   (20853--21256)   403                       ψ*hsdR*    Truncated *hsdR*                                                    92                        dbj\|BAG71456.1\|
  Sk23   22888--23793     906                       *cas1*     CRISPR--associated Cas1 family protein                              91                        gb\|AAW53332.1\|
  Sk24   23793--24098     306                       *cas2*     CRISPR-associated protein Cas2                                      87                        gb\|AAW53331.1\|
  Sk25   24112--26385     2274                      *csm1*     CRISPR-associated protein; Csm1 family                              92                        gb\|AAW53330.1\|
  Sk26   26388--26813     426                       *csm2*     CRISPR-system related protein                                       94                        gb\|AAW53329.1\|
  Sk27   26815--27459     645                       *csm3*     CRISPR-associated RAMP protein                                      96                        gb\|AAW53328.1\|
  Sk28   27530--28378     849                       *csm4*     CRISPR-associated RAMP protein                                      91                        gb\|AAW53327.1\|
  Sk29   28381--29403     1023                      *csm5*     CRISPR-associated Csm5 family protein                               92                        gb\|AAW53326.1\|
  Sk30   29403--30671     1269                      *csm6*     CRISPR-associated protein (Cas_Csm6)                                73                        gb\|AAW53325.1\|
  Sk31   30668--31402     735                       *cas6*     CRISPR-associated protein C                                         86                        gb\|AAW53324.1\|

\*ORF, open reading frame; CRISPR, clustered regularly interspaced short palindromic repeats. †Parentheses indicate complement sequences. ‡None indicates no name given. §Comparisons of translated query versus protein databases was determined by using BLASTX 2.2.21 ([www.ncbi.nlm.nih.gov/blast/Blast.cgi](http://www.ncbi.nlm.nih.gov/blast/Blast.cgi)).

The first unique feature of this SCC*mec*V element included 3 ORFs in the J3 region sharing high sequence identity with ORFs from *S. epidermidis* RP62A (GenBank accession no. CP000029), which included an ADP-ribosylglycohydrolase, a permease for cytosine/purines, and a ribokinase ([Table 3](#T3){ref-type="table"}). A second unique feature was a CRISPR array, identified by using CRISPRFinder ([@R16]), in the J1 region, which appears to have replaced the type 1 restriction modification system (*hsdR*, *hsdS*, *hsdM*) through recombination. The CRISPR array (1,107 bp) contained a 36-bp direct repeat consensus and 15 spacers of variable sequence and length (33--38 bp) ([Figure 3](#F3){ref-type="fig"}). Downstream of this CRISPR array was a combination of putative CRISPR-associated (*cas*) genes, sharing sequence identity with those previously identified in *S. epidermidis* RP62A. This array was followed by a second questionable CRISPR array (183 bp) containing a 38-bp direct repeat consensus and 2 spacers of variable sequence ([Figure 3](#F3){ref-type="fig"}; [Table 3](#T3){ref-type="table"}).

Design of primers spanning the entire SCC*mec* element was based on the DNA sequence obtained from 08 BA 02176 ([Figure 3](#F3){ref-type="fig"}; [Table 4](#T4){ref-type="table"}). PCR of these select regions produced amplicons of expected size for 3 additional LA-MRSA isolates (07 BA 06477, 08 BA 13895, 08 BA 22334) but were negative for some of the J1 and J3 regions in 08 BA 08100 and T40929 ([Table 4](#T4){ref-type="table"}).

###### Primers used for coverage of the novel SCC*mec*V subtype in methicillin-resistant *Staphylococcus aureus* isolates, Canada, 2007--2008\*

  Primer set   Primer name         Primer 5′ → 3′                                Expected amplicon size, bp   Reference position   SCC*mec*V found in isolate                       
  ------------ ------------------- --------------------------------------------- ---------------------------- -------------------- ---------------------------- ---- ---- ---- ---- ----
  1            OrfX Adpr1          CATTTAAGATTATGCGTGGAG CATCTGTAAACTGTCCTTTGG   347                          443--789             \+                           --   \+   \+   --   \+
  2            RibB2 MecaA1        TTGTATATGGGGAAACGAAG TGCCAAAATCTCAGGTAAAG     3623                         3793--7415           \+                           --   \+   \+   --   \+
  3            MecB1 HypA1         CTTCACCATTATCGCTTTTAG ACCATTTTTCCCTGGATTAC    1842                         9172--11013          \+                           \+   \+   \+   \+   \+
  4            Hyp3A1 Hyp1B1       CTTCCACGTATTGGTCTAGC AAGTGAACGCGAAAGATATAG    2671                         11636--14306         \+                           \+   \+   \+   \+   \+
  5            Hyp3B1 CcrCA2       GCTAGACCAATACGTGGAAG TTTTACCTGAAATGCCTGAG     3301                         14287--17587         \+                           \+   \+   \+   \+   \+
  6            CcrCB1 Hyp6A1       ATGAAATGGATAGCGAAATG TTGAGTAAGTAGCGGTGTTG     1330                         18695--20024         \+                           \+   \+   \+   \+   \+
  7            Hyp6B1 Crspr1A1     TGAGCAAGTGATGGAAATG CTTTGAATCCTTTGAAGACG      2835                         20331--23165         \+                           --   \+   \+   --   \+
  8            Crspr1B1 Crspr3A1   AAAAAGTGGTGAGGTTACTTG CTCGTCTATCAATACCACTCG   711                          23675--24385         \+                           --   \+   \+   --   \+
  9            Crspr3B1 Crspr7A1   AACAGATGAACACGGAAAAG TTGGTGGGTATCTCAAAAAG     2417                         26166--28582         \+                           --   \+   \+   --   \+
  10           Crspr7B1 Hyp11A1    GCCTTCTAACGTACCAGTTG TTGCTTCAATGGACTATAAGC    1511                         29289--30820         \+                           --   \+   \+   --   \+
  11           Hyp11B1 Hyp12A1     TTAGGCATGGGGAAATATAG GTCGCAATGTTTTGAAGTG      1622                         31373--              \+                           --   \+   \+   --   \+

\*SCC*mec,* staphylococcal cassette chromosome *mec*V subtype; +, positive; --, negative. Testing by PCR.

Discussion
==========

The high prevalence of LA-MRSA colonization of pigs and pig farmers in Canada ([@R2]) and the United States ([@R3]) and this report of human infections suggest that this LA-MRSA strain from Canada poses potential public and occupational health concern in North America. This strain has been associated with various types of infections in pigs ([@R17],[@R18]) and humans ([@R19],[@R20]) and is transmissible from animal patients to veterinary workers ([@R21]), healthcare workers ([@R22]), and family members ([@R1]). Evidence also suggests that this strain might be spreading from animals to the environment, which may facilitate the colonization or infection of persons who are not involved in animal husbandry ([@R23]). Whereas in 2006 in the Netherlands LA-MRSA accounted for \>20% of all MRSA isolated ([@R24]), carriage of this strain in the general population of 2 provinces in Canada (Manitoba and Saskatchewan) appears rare (0.14%). This difference could be attributed to the substantially higher density of pigs in the Netherlands (1,244 pigs/km^2^) than in Manitoba (55 pigs/km^2^), Saskatchewan (6 pigs/km^2^), and Ontario (91 pigs/km^2^) ([www.agriculture.gov.sk.ca/Pig_Densities](http://www.agriculture.gov.sk.ca/Pig_Densities)). It is also plausible that the much lower proportions of LA-MRSA in Canada, relative to a country with low MRSA endemicity such as the Netherlands, is attributable to competition with other highly successful human epidemic MRSA clones circulating in Canada, including CMRSA2 (USA200/800), CMRSA7 (USA400), and CMRSA10 (USA300) ([@R25],[@R26]).

The tested LA-MRSA isolates were highly susceptible to most classes of antimicrobial drugs, except β-lactams and tetracyclines, the latter of which has been attributed to its high usage in animal husbandry ([@R27]). The complete sequence of the SCC*mec* region showed a novel SCC*mec*V subtype sharing sequence identity in its J1 and J3 regions with chromosomal genes in the *S. epidermidis* RP62A chromosome (GenBank accession no. CP000029), including a CRISPR system. CRISPRs and associated *cas* genes are present in many other bacterial (≈40%) and archaeal (≈90%) genomes ([@R28],[@R29]) and have been shown to be involved in sequence-directed immunity against phages ([@R30],[@R31]) and plasmids ([@R32]). The resistance to plasmids and phages encoded by this system could explain why many of these ST398-MRSA-V strains contain fewer antimicrobial drug resistance genes and phage-encoded virulence factors than do other epidemic MRSA strains ([@R33],[@R34]). The origin of this CRISPR system is unknown, but the propagation of CRISPR loci throughout prokaryote genomes has been proposed to occur through horizontal gene transfer by conjugation of megaplasmids [\>]{.ul}40 kb ([@R35]). Because the CRISPR system identified in this study is encoded within a putative mobile genetic element, we propose that an additional mechanism of mobilization to other methicillin-susceptible *Staphylococcus* spp. is plausible.

This novel subtype of SCC*mec*V was found in only 4 of the 6 LA-MRSA isolates identified in this study. One isolate not containing this novel SCC*mec* subtype (08 BA 08100) could also be distinguished by a different but closely related *spa* type (t1250) ([Table 1](#T1){ref-type="table"}) and variant PFGE fingerprint ([Figure 2](#F2){ref-type="fig"}) when compared with the other LA-MRSA isolates, which suggests that at least 2 epidemiologically different strains of LA-MRSA circulate in Saskatchewan. The other LA-MRSA isolate that did not contain this novel SCC*mec* element was obtained in Ontario. However, this isolate was the same *spa* type (t034) and was closely related, according to PFGE, to the LA-MRSA isolates identified in Saskatchewan. Therefore, in addition to PFGE and *spa* typing, SCC*mec* subtyping could provide a useful epidemiologic tool for surveillance, outbreak investigations, or traceability studies of this emerging strain. For detection of this SCC*mec*V subtype (tentatively designated V.2.1.2; Vb), we propose using primer set 1 (spanning orfX into Sk02 in the J3 region) and primer set 7 (spanning Sk20 into cas1 in the J1 region) ([Table 4](#T4){ref-type="table"}).

Visual comparison of PFGE fingerprints from this study with those reported from patients from the Dominican Republic and the United States (northern Manhattan, New York, NY) ([@R36]), showed substantial variations in fingerprint patterns, as well as related but different *spa* types. These variations suggest further molecular and geographic diversity of these LA-MRSA strains on a global scale.

Because cases of LA-MRSA infections have only recently been identified in Canada, additional surveillance efforts are required to monitor the emergence and clinical relevance of this MRSA strain in Canada, including communities, the environment, livestock, farmers, and production facility workers. Whether these strains pose a major threat to human health in light of the low livestock density and continued spread of epidemic hospital and community strains of MRSA in Canada remains unknown.
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